The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1315
Lacosamide for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved lacosamide (Vimpat – UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.

OTHER DRUGS FOR PARTIAL SEIZURES — Among the older antiepileptic drugs (AEDs), carbamazepine, phenytoin and valproate were traditional first-line treatments for partial seizures. All of the newer agents for epilepsy except felbamate and oxcarbazepine were initially approved as adjunctive therapy for partial seizures. Lamotrigine, topiramate, zonisamide and levetiracetam have a broad spectrum of activity and are now used to treat generalized seizures as well.1

IV formulations are also available for phenytoin, valproate, levetiracetam and phenobarbital.

MECHANISM OF ACTION — Lacosamide is a functional amino acid, structurally related to serine. Its antiepileptic actions appear to be related to slow inactivation ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lacosamide for Epilepsy
Article code: 1315c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian